Clinical value of the symptom–reflux association on secondary treatment outcomes in patients with abnormal acid reflux
Digestion · 2025
DOI: 10.1159/000547213 ↗Kurz gefasst
Fachartikel in der Zeitschrift Digestion, 2025. Verfasst von Satsuki Takahashi und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan. Hauptthemen laut MEDLINE: Gastroesophageal Reflux, Proton Pump Inhibitors.
Abstract (Originalsprache)
Introduction
Multichannel intraluminal impedance and pH monitoring (MII-pH) is the gold standard for diagnosing gastroesophageal reflux disease (GERD). However, the clinical value of the symptom–reflux association (SRA) obtained using MII-pH remains unknown. The current study aimed to investigate the effect of SRA on the efficacy of secondary treatment in refractory true GERD.
Methods
This study included patients who underwent MII-pH monitoring for evaluating proton pump inhibitor (PPI)- or potassium-competitive acid blocker (P-CAB)-refractory GERD symptoms and who were diagnosed with abnormal acid reflux (acid exposure time > 6%). Patients with a positive symptom index (SI) and symptom association probability (SAP) on the MII-pH monitoring were included in the SRA-positive group and the remaining ones in the SRA-negative group. The differences in the subsequent treatment efficacy between the two groups were retrospectively analyzed. Treatment efficacy was evaluated using the Frequency Scale for the Symptoms of GERD (FSSG) questionnaire.
Results
Of the 192 patients with PPI-/PCAB-refractory GERD, 41 (21.4%) were diagnosed with abnormal acid reflux. Among them, 30 (7 in the SRA-positive group and 23 in the SRA-negative group) underwent symptom assessments before and after treatment. The SRA-positive group had a significantly greater symptom improvement after treatment compared with the SRA-negative group (FSSG score changes: −13.0 ± 6.5 vs −5.4 ± 8.2, p = 0.016).
Conclusions
SRA evaluation is effective in predicting secondary treatment outcomes in patients with abnormal acid reflux.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
- Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan, matsumura@chiba-u.jp.
- Department of Clinical Engineering Center, Chiba University Hospital, Chiba, Japan.
Zitieren
APA
Takahashi, S., Matsumura, T., Sonoda, M., Ozaki, T., Kaneko, T., Horio, R., Goto, C., Kurosugi, A., Ohta, Y., Taida, T., Kikuchi, A., Okimoto, K., & Kato, J. (2025). Clinical value of the symptom–reflux association on secondary treatment outcomes in patients with abnormal acid reflux. Digestion. https://doi.org/10.1159/000547213
Vancouver
Takahashi S, Matsumura T, Sonoda M, Ozaki T, Kaneko T, Horio R, et al. Clinical value of the symptom–reflux association on secondary treatment outcomes in patients with abnormal acid reflux. Digestion. 2025. doi:10.1159/000547213
BibTeX
@article{Takahashi2025,
author = {Takahashi, Satsuki and Matsumura, Tomoaki and Sonoda, Michiko and Ozaki, Tomomi and Kaneko, Tatsuya and Horio, Ryosuke and Goto, Chihiro and Kurosugi, Akane and Ohta, Yuki and Taida, Takashi and Kikuchi, Atsuko and Okimoto, Kenichiro and Kato, Jun},
title = {Clinical value of the symptom–reflux association on secondary treatment outcomes in patients with abnormal acid reflux},
journal = {Digestion},
year = {2025},
doi = {10.1159/000547213}
}
EUVIMED